Chinese Clinical Oncology
• 综述与讲座 • Previous Articles Next Articles
JIANG Kan,HUANG Cheng.
Received:
Revised:
Online:
Published:
Contact:
Abstract: Angiogenesis plays an important role in tumor genesis and development. Therefore, anti-angiogenic therapy has become an important part in cancer therapy and throughout the entire therapy process. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) is small molecular anti-angiogenic drug. This article introduces the domestic and international listed and researching VEGFR-TKIs. The models of single-agent/combined with chemotherapy drugs/combined with targeted drugs can improve the objective response rates(ORR)of advanced non-small cell lung cancer (NSCLC), lengthen progression-free survival(PFS). But it was failed to lengthen overall survival(OS). And the adverse effects of VEGFR-TKIs were greater. How to improve the efficacy and reduce adverse effects will be the direction of future research.
JIANG Kan,HUANG Cheng. . Progression of VEGFR-TKI in advanced non-small cell lung cancer[J].Chinese Clinical Oncology, 2017, 22(9): 845-.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/
http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/Y2017/V22/I9/845
Cited